Small-cell lung cancer (SCLC) is a highly aggressive cancer type with immunosuppressed phenotype. Here, the authors find that depletion of nonhomologous end joining DNA repair regulator PRKDC is able to induce activation of the cGAS/STING pathway and potentiate the efficacy of immunotherapy in SCLC pre-clinical models.
- Subhamoy Chakraborty
- Andrew Elliott
- Triparna Sen
